UC Researcher Receives $1.7 Million Grant to Study Cardiac Hypertrophy
CINCINNATIA new $1.7 million National Institutes of Health grant will help University of Cincinnati (UC) researchers continue their investigation of the protein Human Antigen R (HuR) and its possible role in cardiovascular disease, with the ultimate goal of translating this research to improve human health.
Using animal models of heart disease, researchers are able to surgically restrict the amount of blood flowing through the aorta resulting in an increase in the pressure the heart must pump against, causing cardiac muscle to enlarge, called hypertrophy. Cardiac hypertrophy often progresses to heart failure, and there are currently no treatments for the underlying cause of hypertrophy at the level of the myocyte, or cardiac muscle cell.
"What we have found is when we delete this protein in the myocytes, normal cardiac function is unaffected, but the mice lacking HuR are protected from hypertrophy and heart failure, explains Michael Tranter, assistant professor in the UC College of Medicines Division of Cardiovascular Health and Disease. "All of our evidence so far suggests that activation of HuR in the adult heart is only affecting the pathology, making it an ideal target.
Tranter, a researcher at the UC Heart, Lung and Vascular Institute, received a five-year grant (R01HL132111) from the NIHs National Heart, Lung and Blood Institute, to determine why and how the HuR protein is activated and how to duplicate the process. The grants principal investigator Tranter is also collaborating with co-investigator, Jack Rubinstein, MD, assistant professor in the UC College of Medicine and UC Health cardiologist.
Rubinstein says Tranters research will be very helpful in understanding how the heart reacts when subjected to high blood pressure.
"This line of research is particularly important as hundreds of thousands of people, especially older patients, develop heart problems, including heart failure as a result of suffering from high blood pressure, says Rubinstein. The American Heart Association estimates that roughly one in four Americans currently suffers from high blood pressure.
Tranter and Rubinstein, along with colleagues Phillip Owens, PhD, and Kevin Haworth, PhD, both also assistant professors in UC College of Medicines Division of Cardiovascular Health and Disease, are part of a recent investment in young investigators by the College of Medicine. While their average age is only 36, they have together already been awarded over $4 million in external research funding from sources such as the NIH and the American Heart Association. At age 34, Tranter is nearly a decade younger than the average first-time NIH R01 grant recipient.
Related Stories
UC radiation oncologist speaks with Local 12 news about clinical trial for head and neck cancer treatment
August 10, 2026
Dr. Sara Medek, a UC radiation oncology professor, speaks with Local 12 news about a new clinical trial aimed at reducing radiation in certain areas while still treating cancer effectively but with fewer painful side effects.
Cancer Center director charts future based on collaboration, AI
August 10, 2026
David Gius, MD, PhD, was featured in a Cincinnati Business Courier article and The Cancer Letter’s “The Directors" podcast discussing his priorities and goals as he recently took the helm as director of the University of Cincinnati Cancer Center.
UC graduates cross finish line at commencement
August 7, 2026
The University of Cincinnati recognized 2,125 graduates in two ceremonies at summer commencement Friday on campus at Fifth Third Arena.